ImmuCell Corporation
ICCC
$9.91
$0.070.71%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 7.19M | 10.36M | 7.63M | 5.51M | 6.44M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 7.19M | 10.36M | 7.63M | 5.51M | 6.44M |
| Cost of Revenue | 4.75M | 5.70M | 4.72M | 3.14M | 3.63M |
| Gross Profit | 2.44M | 4.66M | 2.91M | 2.36M | 2.82M |
| SG&A Expenses | 2.38M | 2.37M | 1.41M | 1.65M | 1.42M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -2.00M | -- | -- | -- | -- |
| Total Operating Expenses | 5.25M | 8.39M | 6.88M | 5.49M | 5.88M |
| Operating Income | 1.93M | 1.97M | 742.00K | 20.10K | 569.60K |
| Income Before Tax | 1.88M | 1.95M | -2.85M | -135.30K | 503.80K |
| Income Tax Expenses | 46.00K | 12.50K | 3.30K | 4.50K | 1.90K |
| Earnings from Continuing Operations | 1.83M | 1.94M | -2.85M | -139.70K | 501.90K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 1.83M | 1.94M | -2.85M | -139.70K | 501.90K |
| EBIT | 1.93M | 1.97M | 742.00K | 20.10K | 569.60K |
| EBITDA | 2.41M | 2.50M | 1.45M | 699.20K | 1.24M |
| EPS Basic | 0.20 | 0.21 | -0.32 | -0.02 | 0.06 |
| Normalized Basic EPS | 0.13 | 0.13 | 0.05 | -0.01 | 0.03 |
| EPS Diluted | 0.20 | 0.21 | -0.32 | -0.02 | 0.06 |
| Normalized Diluted EPS | 0.13 | 0.13 | 0.05 | -0.01 | 0.03 |
| Average Basic Shares Outstanding | 9.06M | 9.05M | 9.05M | 9.05M | 9.03M |
| Average Diluted Shares Outstanding | 9.19M | 9.05M | 9.19M | 9.05M | 9.03M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |